Largest pharmaceutical companies by revenue
Everything the company sold in its latest fiscal year, before any cost is taken off.
Johnson & Johnson leads the 52 pharmaceutical companies ranked by revenue, at AED 346B, ahead of Eli Lilly (AED 239.4B) and Merck & Co (AED 238.8B). Figures as of 18 Nov 2026, 22:17 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 52
- First
- Johnson & JohnsonAED 346B
- Median
- AED 11.8B
- Combined market value
- AED 18.58T
- Countries
- 10
- Not ranked
- 9no revenue on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | Revenue ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Johnson & JohnsonJNJ · Health Care | AED 346B | AED 2.41T | AED 1,001.57 | 2.15% down | 38% up | ||
| 2 | Eli LillyLLY · Health Care | AED 239.4B | AED 4.52T | AED 5,078.56 | 2.32% down | 35% up | ||
| 3 | Merck & CoMRK · Health Care | AED 238.8B | AED 1.25T | AED 506.04 | 3.90% down | 51% up | ||
| 4 | PfizerPFE · Health Care | AED 229.8B | AED 587.4B | AED 103.06 | 1.44% down | 14% up | ||
| 5 | AbbVieABBV · Health Care | AED 224.6B | AED 1.86T | AED 1,050.46 | 2.33% down | 26% up | ||
| 6 | AstraZenecaAZN · Health Care | AED 215.7B | AED 1.02T | AED 656.55 | 1.93% down | 2% up | ||
| 7 | NovartisNVS · Health Care | AED 200.3B | AED 1.08T | AED 570.06 | 2.46% down | 25% up | ||
| 8 | SanofiSNY · Health Care | AED 177.8B | AED 415.6B | AED 173.06 | 0.86% down | 4% down | ||
| 9 | Bristol-Myers SquibbBMY · Health Care | AED 177B | AED 447.1B | AED 218.75 | 2.92% down | 34% up | ||
| 10 | Novo NordiskNVO · Health Care | AED 168.5B | AED 638.3B | AED 144.82 | 3.12% down | 17% down | ||
| 11 | Abbott LaboratoriesABT · Health Care | AED 162.8B | AED 664.6B | AED 383.73 | 0.22% down | 17% down | ||
| 12 | GSKGSK · Health Care | AED 159.3B | AED 357.6B | AED 178.42 | 1.34% down | 6% up | ||
| 13 | Takeda PharmaceuticalTAK · Health Care | AED 103.6B | AED 249.6B | AED 78.12 | 1.71% down | 54% up | ||
| 14 | Teva Pharmaceutical IndustriesTEVA · Health Care | AED 63.4B | AED 181B | AED 155.10 | 0.92% down | 74% up | ||
| 15 | Regeneron PharmaceuticalsREGN · Health Care | AED 52.7B | AED 359.2B | AED 3,472.74 | 1.28% down | 36% up | ||
| 16 | ViatrisVTRS · Health Care | AED 52.5B | AED 85.4B | AED 74.48 | 0.83% down | 96% up | ||
| 17 | Vertex PharmaceuticalsVRTX · Health Care | AED 44.1B | AED 499.5B | AED 1,970.27 | 0.42% up | 27% up | ||
| 18 | ZoetisZTS · Health Care | AED 34.8B | AED 127.7B | AED 314.28 | 2.50% up | 29% down | ||
| 19 | GrifolsGRFS · Health Care | AED 30.7B | AED 21.2B | AED 31.11 | 1.85% down | 1% up | ||
| 20 | BeOne MedicinesONC · Health Care | AED 19.6B | AED 169.3B | AED 1,482.34 | 2.34% down | 17% up | ||
| 21 | Elanco Animal HealthELAN · Health Care | AED 17.3B | AED 49B | AED 98.06 | 3.29% up | 20% up | ||
| 22 | Jazz PharmaceuticalsJAZZ · Health Care | AED 15.7B | AED 58.4B | AED 910.01 | 2.93% up | 37% up | ||
| 23 | GenmabGMAB · Health Care | AED 13.7B | AED 115.4B | AED 187.20 | 1.91% down | 70% up | ||
| 24 | Alnylam PharmaceuticalsALNY · Health Care | AED 13.6B | AED 73.5B | AED 548.72 | 4.54% down | 66% down | ||
| 25 | Dr. Reddy's LaboratoriesRDY · Health Care | AED 13.1B | AED 45.9B | AED 55.02 | 1.28% up | 5% up | ||
| 26 | BioMarin PharmaceuticalBMRN · Health Care | AED 11.8B | AED 43.7B | AED 225.62 | 4.99% up | 11% up | ||
| 27 | United TherapeuticsUTHR · Health Care | AED 11.7B | AED 90.3B | AED 2,120.45 | 1.16% down | 23% up | ||
| 28 | Amneal PharmaceuticalsAMRX · Health Care | AED 11.1B | AED 28B | AED 80.36 | 3.60% up | 83% up | ||
| 29 | Royalty PharmaRPRX · Health Care | AED 8.7B | AED 145B | AED 252.21 | 0.01% down | 78% up | ||
| 30 | PTC TherapeuticsPTCT · Health Care | AED 6.4B | AED 18.5B | AED 221.21 | 0.22% down | 20% down | ||
| 31 | AlkermesALKS · Health Care | AED 5.4B | AED 28.9B | AED 172.07 | 3.08% up | 58% up | ||
| 32 | Legend BiotechLEGN · Health Care | AED 3.8B | AED 11.6B | AED 59.68 | 0.87% up | 42% down | ||
| 33 | Madrigal PharmaceuticalsMDGL · Health Care | AED 3.5B | AED 34B | AED 1,462.07 | 5.67% down | 24% down | ||
| 34 | Ionis PharmaceuticalsIONS · Health Care | AED 3.5B | AED 16.8B | AED 100.60 | 1.59% up | 64% down | ||
| 35 | Arrowhead PharmaceuticalsARWR · Health Care | AED 3B | AED 22.4B | AED 158.33 | 0.28% up | 10% up | ||
| 36 | Ascendis PharmaASND · Health Care | AED 2.9B | AED 65.1B | AED 992.87 | 0.32% down | 28% up | ||
| 37 | Corcept TherapeuticsCORT · Health Care | AED 2.8B | AED 27.2B | AED 248.98 | 3.25% down | 8% down | ||
| 38 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | AED 2.5B | AED 27.4B | AED 349.10 | 0.06% down | 126% up | ||
| 39 | Axsome TherapeuticsAXSM · Health Care | AED 2.3B | AED 25.9B | AED 492.16 | 1.43% down | 7% down | ||
| 40 | TG TherapeuticsTGTX · Health Care | AED 2.3B | AED 36.7B | AED 242.85 | 5.44% up | 107% up | ||
| 41 | InsmedINSM · Health Care | AED 2.2B | AED 96.5B | AED 440.00 | 1.69% down | 40% down | ||
| 42 | Mirum PharmaceuticalsMIRM · Health Care | AED 1.9B | AED 22.2B | AED 339.70 | 0.59% up | 31% up | ||
| 43 | BridgeBio PharmaBBIO · Health Care | AED 1.8B | AED 55.8B | AED 286.52 | 1.58% up | 17% up | ||
| 44 | Travere TherapeuticsTVTX · Health Care | AED 1.8B | AED 17.7B | AED 184.52 | 1.68% down | 44% up | ||
| 45 | Ligand PharmaceuticalsLGND · Health Care | AED 984.6M | AED 21.9B | AED 1,097.10 | 1.67% up | 43% up | ||
| 46 | Rhythm PharmaceuticalsRYTM · Health Care | AED 696.9M | AED 30.3B | AED 437.21 | 2.08% up | 13% up | ||
| 47 | CytokineticsCYTK · Health Care | AED 323.3M | AED 26.3B | AED 188.49 | 0.64% down | 20% down | ||
| 48 | Protagonist TherapeuticsPTGX · Health Care | AED 169M | AED 30.5B | AED 467.03 | 2.00% up | 46% up | ||
| 49 | Roivant SciencesROIV · Health Care | AED 30.3M | AED 103.1B | AED 142.25 | 0.05% up | 90% up | ||
| 50 | Dianthus TherapeuticsDNTH · Health Care | AED 7.5M | AED 17.4B | AED 308.44 | 3.45% down | 113% up | ||
| 51 | Spyre TherapeuticsSYRE · Health Care | AED 0 | AED 35.4B | AED 372.64 | 8.15% up | 286% up | ||
| 52 | Praxis Precision MedicinesPRAX · Health Care | AED 0 | AED 31.3B | AED 1,120.90 | 0.04% up | 61% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Revenue is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 3.6728 AED). 9 companies have no revenue on file and are not ranked here.
Questions and answers
Which pharmaceutical companies rank first by revenue?
Johnson & Johnson (AED 346B), Eli Lilly (AED 239.4B) and Merck & Co (AED 238.8B) are the top three of the 52 pharmaceutical companies ranked by revenue as of 18 Nov 2026, 22:17 UTC.
How many pharmaceutical companies are in this ranking?
52 are ranked by revenue. 9 more have no revenue on file and are left out rather than ranked at zero.
What are these pharmaceutical companies worth together?
The 52 pharmaceutical companies ranked by revenue have a combined market value of AED 18.58T as of 18 Nov 2026, 22:17 UTC.
What does ranking by revenue measure?
Everything the company sold in its latest fiscal year, before any cost is taken off.
Learn how this ranking works
All markets guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
- How companies are sorted into sectors and industries
Companies are sorted into sectors and industries by classification systems. The index providers MSCI and S&P Dow Jones Indices use GICS: 11 sectors split into 25 industry groups, 74 industries and 163 sub-industries. SEC filings carry a four-digit SIC code. The two can place one company differently, because each looks at the business from its own angle.
Cite this page
Funkfolio, “Largest pharmaceutical companies by revenue”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=revenue
Underlying data: Yahoo Finance; SEC EDGAR.